2022 Announcements

CLINUVEL
Posted by CLINUVEL
April 1, 2022

DNA Repair Communiqué II

In this DNA Repair Communiqué II we delve deeper into the topic...

Read More
CLINUVEL
Posted by CLINUVEL
March 31, 2022

CLINUVEL Communiqué II

At CLINUVEL our path has been set and we continue to grow...

Read More
CLINUVEL
Posted by CLINUVEL
March 30, 2022

First XP-V Patient Treated in CLINUVEL DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
March 23, 2022

Change of Director's Interest Notice

Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 17, 2022

ACTH Manufacturing Update

CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...

Read More
CLINUVEL
Posted by CLINUVEL
March 15, 2022

Afamelanotide in stroke (AIS) – positive preliminary results

CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2022

Change of Director's Interest Notice

Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
Lachlan Hay
Posted by Lachlan Hay
February 28, 2022

CEO letter

On 24 February, the world plunged into instability, initiated by delusional warfare...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

CLINUVEL Reports Record December Half Year Operating Profit

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 16, 2022

Financial Results Half Year Ended, 31 December 2021

CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...

Read More
CLINUVEL
Posted by CLINUVEL
February 15, 2022

DNA Repair Communiqué I

This first Communiqué in a series on DNA forms an introductory foundation,...

Read More
CLINUVEL
Posted by CLINUVEL
February 14, 2022

CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
January 31, 2022

Appendix 4C & Activity Report

Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL.
Posted by CLINUVEL.
January 28, 2022

CLINUVEL Kommuniqué 1

Happy New Year to all our stakeholders for 2022, a year in...

Read More